Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Non-infectious pulmonary complications after haematopoietic progenitor transplantation: a diagnostic approach.Journal of thoracic disease · 2024
   Review
2. Hematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview.Children (Basel, Switzerland) · 2023
   Article
3. Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.European respiratory review : an official journal of the European Respiratory Society · 2021
   Review
4. Noninfectious pulmonary complications of haematopoietic stem cell transplantation.European respiratory review : an official journal of the European Respiratory Society · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as